1. A Single Office-Based Stool Blood Test (FOBT) Is a Poor, but Often Used, Screening Test for Colorectal Cancer Two articles and an editorial in the Jan. 18, 2005, Annals of Internal Medicine discuss ...

TO THE EDITORS:In the July issue of The American Journal of Managed Care, Schroy et al 1 reported on preferences for colorectal cancer (CRC) screening tests in relation to currently recommended ...

For patients with a positive fecal occult blood test in a cohort study, those who did not undergo a follow-up colonoscopy had an increased incidence of colorectal cancer. Those who underwent ...

Impact on stage distribution of gastric cancer by the National Cancer Screening Program (NCSP) in Korea. Background: Mass screening programs for colorectal cancer are based on fecal occult blood test ...

Please provide your email address to receive an email when new articles are posted on . Patients who received a positive fecal occult blood test as an initial screening for colorectal cancer may need ...

Please provide your email address to receive an email when new articles are posted on . The COVID-19 pandemic created new barriers for colorectal cancer screening. However, fecal occult blood tests ...

A survey was designed and distributed electronically to Ukrainian PCPs, focusing on CRC screening practices, beliefs, and barriers. The survey incorporated questions adapted from established cancer ...

Stool-based tests for colorectal cancer (CRC) screening show no significant difference in detecting advanced neoplasia overall, but for advanced serrated lesions specifically, the multitarget stool ...

Last Monday I got my “At-Home Stool Test Kit” in the mail. This test is called “fecal immunochemical tests” (FITs). This test is done at home and detects tiny amounts of blood in your stool, which is ...

Fecal occult-blood testing (FOBT) is a noninvasive, effective means of screening for colorectal cancer (CRC). The SENSITIVITY of this technique is suboptimal, however, and identification of a simple, ...

Expensive colonoscopies that cost a patient over $1,000 on average could soon be replaced by simpler and much cheaper tests as non-invasive screening options become more available and more ...